The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease

Bibliography

• Daffu G, del Pozo CH, O’Shea KM, et al. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci. 2013;14:19891–19910.
   PubMed Web of Science ®Google Scholar
• Litwinoff EM, Hurtado Del Pozo C, Ramasamy R, et al. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin Pharmacol Ther. 2015;98(2):135–144. doi:10.1002/cpt.148.
   PubMed Web of Science ®Google Scholar
• Manigrasso MB, Juranek J, Ramasamy R, et al. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab. 2014;25:15–22.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol. 2012;57:160–167.
   PubMed Web of Science ®Google Scholar
• Kislinger T, Fu C, Huber B, et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749.
   PubMed Web of Science ®Google Scholar
• Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51:2082–2089.
   PubMed Web of Science ®Google Scholar
• McVicar CM, Ward M, Colhoun LM, et al. Role of the receptor for advanced glycation endproducts (RAGE) in retinal vasodegenerative pathology during diabetes in mice. Diabetologia. 2015;58:1129–1137.
   PubMed Web of Science ®Google Scholar
• Reiniger N, Lau K, McCalla D, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes. 2010;59:2043–2054.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354–360.
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–691.
   PubMed Web of Science ®Google Scholar
• Rai V, Toure F, Chitayat S, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med. 2012;209:2339–2350.
   PubMed Web of Science ®Google Scholar
• Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507–1515.
   PubMed Web of Science ®Google Scholar
• He M, Kubo H, Morimoto K, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011;12:358–364.
   PubMed Web of Science ®Google Scholar
• Maillard-Lefebvre H, Boulanger E, Daroux M, et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009;48:1190–1196.
   PubMed Web of Science ®Google Scholar
• Vazzana N, Santilli F, Cuccurullo C, et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4:389–401.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets. 2007;8:1138–1143.
   PubMed Web of Science ®Google Scholar
• Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22:3716–3727.
   PubMed Web of Science ®Google Scholar
• Zhang L, Bukulin M, Kojro E, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283:35507–35516.
   PubMed Web of Science ®Google Scholar
• Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–1109.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–S9.
   PubMed Web of Science ®Google Scholar
• Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell. 2010;9:776–784.
   PubMed Web of Science ®Google Scholar
• Gu Q, Wang B, Zhang XF, et al. Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats. Eur J Pharmacol. 2014;741:186–194.
   PubMed Web of Science ®Google Scholar
• Grossin N, Auger F, Niquet-Leridon C, et al. Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol Nutr Food Res. 2015;59:927–938.
   PubMed Web of Science ®Google Scholar
• Kotani K, Caccavello R, Sakane N, et al. Influence of physical activity intervention on circulating soluble receptor for advanced glycation end products in elderly subjects. J Clin Med Res. 2011;3:252–257.
   PubMedGoogle Scholar
• Tanji N, Markowitz GS, Fu C, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol. 2000;11:1656–1666.
   PubMed Web of Science ®Google Scholar
• Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266–1271.
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025–1031.
   PubMed Web of Science ®Google Scholar
• Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008;57:2461–2469.
   PubMed Web of Science ®Google Scholar
• Bu DX, Rai V, Shen X, et al. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res. 2010;106:1040–1051.
   PubMed Web of Science ®Google Scholar
• Sun L, Ishida T, Yasuda T, et al. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice. Cardiovasc Res. 2009;82:371–381.
   PubMed Web of Science ®Google Scholar
• Harja E, Bu DX, Hudson BI, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118:183–194.
   PubMed Web of Science ®Google Scholar
• Koulis C, Kanellakis P, Pickering RJ, et al. Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. Clin Sci (Lond). 2014;127:485–497.
   PubMed Web of Science ®Google Scholar
• Bro S, Flyvbjerg A, Binder CJ, et al. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis. 2008;201:274–280.
   PubMed Web of Science ®Google Scholar
• Liu M, Yu Y, Jiang H, et al. Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin. 2013;34:830–836.
   PubMed Web of Science ®Google Scholar
• Watson AM, Gray SP, Jiaze L, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes. 2012;61:2105–2113.
   PubMed Web of Science ®Google Scholar
• Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes. 2006;55:2510–2522.
   PubMed Web of Science ®Google Scholar
• Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123–1137.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108:261–268.
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 2004;53:166–172.
   PubMed Web of Science ®Google Scholar
• Tesch G, Sourris KC, Summers SA, et al. Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes. Diabetologia. 2014;57:1977–1985.
   PubMed Web of Science ®Google Scholar
• Jung E, Kim J, Ho Kim S, et al. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. Eur J Pharmacol. 2015;761:116–124.
   PubMed Web of Science ®Google Scholar
• Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015;47(9):686–692. doi:10.1055/s-0034-1395609.
   Web of Science ®Google Scholar
• Fukami K, Yamagishi S, Coughlan MT, et al. Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr. 2014;6:86.
   PubMed Web of Science ®Google Scholar
• Matsui T, Yamagishi S, Takeuchi M, et al. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun. 2010;398:326–330.
   PubMed Web of Science ®Google Scholar
• Nentwich MM, Ulbig MW. Diabetic retinopathy – ocular complications of diabetes mellitus. World J Diabetes. 2015;6:489–499.
   PubMed Web of Science ®Google Scholar
• Dahrouj M, Desjardins DM, Liu Y, et al. Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure. Exp Eye Res. 2015;137:50–56.
   PubMed Web of Science ®Google Scholar
• Zong H, Ward M, Madden A, et al. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia. 2010;53:2656–2666.
   PubMed Web of Science ®Google Scholar
• Warboys CM, Toh HB, Fraser PA. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci. 2009;50:1319–1328.
   PubMed Web of Science ®Google Scholar
• Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007;48:858–865.
   PubMed Web of Science ®Google Scholar
• Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2916–2924.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Schmidt AM. Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep. 2012;9:107–116.
   PubMedGoogle Scholar
• Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14:953–961.
   PubMed Web of Science ®Google Scholar
• Sorci G, Riuzzi F, Giambanco I, et al. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta. 2013;1833:101–109.
   PubMed Web of Science ®Google Scholar
• Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159:513–525.
   PubMed Web of Science ®Google Scholar
• Christaki E, Lazaridis N, Opal SM. Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis? Curr Opin Infect Dis. 2012;25:304–311.
   PubMed Web of Science ®Google Scholar
• Guo L, Chen Z, Amarnath V, et al. Isolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts. Antioxid Redox Signal. 2015;22:1633–1645.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Cai W, Woodward M, et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? J Clin Endocrinol Metab. 2015;100:1957–1966.
   PubMed Web of Science ®Google Scholar
• Gaens KH, Goossens GH, Niessen PM, et al. Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol. 2014;34:1199–1208.
   PubMed Web of Science ®Google Scholar
• Song F, Hurtado del Pozo C, Rosario R, et al. RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes. 2014;63:1948–1965.
   PubMed Web of Science ®Google Scholar
• Fujiya A, Nagasaki H, Seino Y, et al. The role of S100B in the interaction between adipocytes and macrophages. Obesity (Silver Spring, Md). 2014;22:371–379.
   PubMed Web of Science ®Google Scholar
• Chen Y, Akirav EM, Chen W, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008;181:4272–4278.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yan SS, Colgan J, et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004;173:1399–1405.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Hudson BI, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 2002;3:123–135.
   PubMed Web of Science ®Google Scholar
• Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 2014;47:77–94.
   PubMed Web of Science ®Google Scholar
• Katz J, Stavropoulos F, Bhattacharyya I, et al. Receptor of advanced glycation end product (RAGE) expression in the minor salivary glands of patients with Sjogren’s syndrome: a preliminary study. Scand J Rheumatol. 2004;33:174–178.
   PubMed Web of Science ®Google Scholar
• Goury A, Meghraoui-Kheddar A, Belmokhtar K, et al. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice. J Immunol. 2015;194:3612–3622.
   PubMed Web of Science ®Google Scholar
• Matsuura E, Kobayashi K, Lopez LR. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep. 2009;11:61–69.
   PubMedGoogle Scholar
• Nienhuis HL, Westra J, Smit AJ, et al. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity. 2009;42:302–304.
   PubMed Web of Science ®Google Scholar
• Zeng S, Zhang QY, Huang J, et al. Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J. 2012;26:882–893.
   PubMed Web of Science ®Google Scholar
• Malik P, Chaudhry N, Mittal R, et al. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochim Biophys Acta. 2015;1850:1898–1904.
   PubMed Web of Science ®Google Scholar
• Chang YH, Chen CM, Chen HY, et al. Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma. Sci Rep. 2015;5:10979.
   PubMed Web of Science ®Google Scholar
• Medapati MR, Dahlmann M, Ghavami S, et al. RAGE mediates the pro-migratory response of extracellular S100A4 in human thyroid cancer cells. Thyroid. 2015;25:514–527.
   PubMed Web of Science ®Google Scholar
• Zhu L, Ren L, Chen Y, et al. Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med. 2015;19(9):2128-2135. doi:10.1111/jcmm.12577.
   Web of Science ®Google Scholar
• Shen Z, Deng H, Fang Y, et al. Identification of the interplay between SOX9 and S100P in the metastasis and invasion of colon carcinoma. Oncotarget. 2015;6(24):20672–20684.
   Web of Science ®Google Scholar
• Khorramdelazad H, Bagheri V, Hassanshahi G, et al. S100A12 and RAGE expression in human bladder transitional cell carcinoma: a role for the ligand/RAGE axis in tumor progression? Asian Pac J Cancer Prev. 2015;16:2725–2729.
   PubMedGoogle Scholar
• Nasser MW, Wani NA, Ahirwar DK, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015;75:974–985.
   PubMed Web of Science ®Google Scholar
• Reeb AN, Li W, Sewell W, et al. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2015;100:E232–42.
   Google Scholar
• Duan Z, Chen G, Chen L, et al. Determinants of concentrations of N(epsilon)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancer. Int J Mol Epidemiol Genet. 2014;5:152–163.
   PubMedGoogle Scholar
• Yang M, Zeng P, Kang R, et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. PLoS One. 2014;9:e97242.
   PubMed Web of Science ®Google Scholar
• Yin C, Li H, Zhang B, et al. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition. Breast Cancer Res Treat. 2013;142:297–309.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang L, Zhang IY, et al. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res. 2013;19:3764–3775.
   PubMed Web of Science ®Google Scholar
• Yan W, Chang Y, Liang X, et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 2012;55:1863–1875.
   PubMed Web of Science ®Google Scholar
• Shubbar E, Vegfors J, Carlstrom M, et al. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat. 2012;134:71–80.
   PubMed Web of Science ®Google Scholar
• Jin Q, Chen H, Luo A, et al. S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One. 2011;6:e19375.
   Google Scholar
• Nasser MW, Qamri Z, Deol YS, et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res. 2012;72:604–615.
   PubMed Web of Science ®Google Scholar
• Nagy N, Brenner C, Markadieu N, et al. S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration. Lab Invest. 2001;81:599–612.
   PubMed Web of Science ®Google Scholar
• Elangovan I, Thirugnanam S, Chen A, et al. Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochem Biophys Res Commun. 2012;417:1133–1138.
   PubMed Web of Science ®Google Scholar
• Juranek JK, Geddis MS, Song F, et al. RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes. 2013;62:931–943.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Riehl A, Durchdewald M, et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008;205:275–285.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang L, Zhang IY, et al. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res. 2014;74:7285–7297.
   PubMed Web of Science ®Google Scholar
• Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem. 2010;285:23233–23240.
   PubMed Web of Science ®Google Scholar
• Shang L, Ananthakrishnan R, Li Q, et al. RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One. 2010;5:e10092.
   Web of Science ®Google Scholar
• Chang JS, Wendt T, Qu W, et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res. 2008;102:905–913.
   PubMed Web of Science ®Google Scholar
• Yan SF, Fujita T, Lu J, et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med. 2000;6:1355–1361.
   PubMed Web of Science ®Google Scholar
• Iannitti RG, Casagrande A, De Luca A, et al. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med. 2013;188:1338–1350.
   PubMed Web of Science ®Google Scholar
• Tafani M, Schito L, Pellegrini L, et al. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B. Carcinogenesis. 2011;32:1167–1175.
   PubMed Web of Science ®Google Scholar
• Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143:1699–1712.
   PubMed Web of Science ®Google Scholar
• Marinakis E, Bagkos G, Piperi C, et al. Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention? Clin Chem Lab Med. 2014;52:189–200.
   PubMed Web of Science ®Google Scholar
• Shirasawa M, Fujiwara N, Hirabayashi S, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells. 2004;9:165–174.
   PubMed Web of Science ®Google Scholar
• Fehrenbach H, Kasper M, Tschernig T, et al. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand). 1998;44:1147–1157.
   PubMed Web of Science ®Google Scholar
• Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res. 1997;57:3669–3671.
   PubMed Web of Science ®Google Scholar
• Bartling B, Hofmann HS, Weigle B, et al. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis. 2005;26:293–301.
   PubMed Web of Science ®Google Scholar
• Ramsgaard L, Englert JM, Tobolewski J, et al. The role of the receptor for advanced glycation end-products in a murine model of silicosis. PLoS One. 2010;5:e9604.
   Google Scholar
• He M, Kubo H, Ishizawa K, et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1427–L1436.
   PubMed Web of Science ®Google Scholar
• Ramsgaard L, Englert JM, Manni ML, et al. Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS One. 2011;6:e20132.
   PubMed Web of Science ®Google Scholar
• Mazarati A, Maroso M, Iori V, et al. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Exp Neurol. 2011;232:143–148.
   PubMed Web of Science ®Google Scholar
• Guglielmotto M, Aragno M, Tamagno E, et al. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging. 2012;33(196):e13–e27.
   Google Scholar
• Cho HJ, Son SM, Jin SM, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer’s disease animal model. FASEB J. 2009;23:2639–2649.
   PubMed Web of Science ®Google Scholar
• Wang X, Yu S, Hu JP, et al. Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-kappaB pathway. Int J Neurosci. 2014;124:601–608.
   PubMed Web of Science ®Google Scholar
• Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease. Brain Res. 2008;1230:273–280.
   PubMed Web of Science ®Google Scholar
• Li K, Dai D, Zhao B, et al. Association between the RAGE G82S polymorphism and Alzheimer’s disease. J Neural Transm. 2010;117:97–104.
   PubMed Web of Science ®Google Scholar
• Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J. 2010;24:1043–1055.
   PubMed Web of Science ®Google Scholar
• Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer’s disease. Curr Pharm Des. 2008;14:1601–1605.
   PubMed Web of Science ®Google Scholar
• Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405–415.
   PubMed Web of Science ®Google Scholar
• Arancio O, Zhang HP, Chen X, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004;23:4096–4105.
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol. 2001;171:29–45.
   PubMed Web of Science ®Google Scholar
• Choi BR, Cho WH, Kim J, et al. Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer’s disease. Exp Mol Med. 2014;46:e75.
   Google Scholar
• Askarova S, Yang X, Sheng W, et al. Role of Abeta-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A(2) activation in astrocytes and cerebral endothelial cells. Neuroscience. 2011;199:375–385.
   PubMed Web of Science ®Google Scholar
• Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122:1377–1392.
   PubMed Web of Science ®Google Scholar
• Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014;82:1536–1542.
   PubMed Web of Science ®Google Scholar
• Walker D, Lue LF, Paul G, et al. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24:393–399.
   PubMed Web of Science ®Google Scholar
• Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008;283:34457–34468.
   PubMed Web of Science ®Google Scholar
• Kühn S, Geyer M. Formins as effector proteins of Rho GTPases. Small GTPases. 2014;5:e29513.
   PubMedGoogle Scholar
• Young KG, Copeland JW. Formins in cell signaling. Biochim Biophys Acta. 2010;1803:183–190.
   PubMed Web of Science ®Google Scholar
• Bianchi R, Kastrisianaki E, Giambanco I, et al. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem. 2011;286:7214–7226.
   PubMed Web of Science ®Google Scholar
• Toure F, Fritz G, Li Q, et al. Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res. 2012;110:1279–1293.
   PubMed Web of Science ®Google Scholar
• Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003;111:959–972.
   PubMed Web of Science ®Google Scholar
• Rai V, Maldonado AY, Burz DS, et al. Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem. 2012;287:5133–5144.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Murata H, Putranto EW, et al. DOCK7 is a critical regulator of the RAGE-Cdc42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells. Oncol Rep. 2013;29:1073–1079.
   PubMed Web of Science ®Google Scholar
• Koch M, Chitayat S, Dattilo BM, et al. Structural basis for ligand recognition and activation of RAGE. Structure. 2010;18:1342–1352.
   PubMed Web of Science ®Google Scholar
• Park H, Adsit FG, Boyington JC. The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem. 2010;285:40762–40770.
   PubMed Web of Science ®Google Scholar
• Xue J, Rai V, Singer D, et al. Advanced glycation end product recognition by the receptor for AGEs. Structure. 2011;19:722–732.
   PubMed Web of Science ®Google Scholar
• Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther. 2014;6:89.
   PubMed Web of Science ®Google Scholar
• Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–1037.
   PubMed Web of Science ®Google Scholar
• Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–1729.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60:2379–2385.
   PubMed Web of Science ®Google Scholar
• Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med. 2009;180:1010–1015.
   PubMed Web of Science ®Google Scholar
• Cheng DT, Kim DK, Cockayne DA, et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:948–957.
   PubMed Web of Science ®Google Scholar
• Parikh M, Chung M, Sheth S, et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014;260:617–622. discussion 22-4.
   PubMed Web of Science ®Google Scholar
• Reverdatto S, Rai V, Xue J, et al. Combinatorial library of improved peptide aptamers, CLIPs to inhibit RAGE signal transduction in mammalian cells. PLoS One. 2013;8:e65180.
   PubMed Web of Science ®Google Scholar
• Ku SH, Hong J, Moon HH, et al. Deoxycholic acid-modified polyethylenimine based nanocarriers for RAGE siRNA therapy in acute myocardial infarction. Arch Pharm Res. 2015;38(7):1317–1324. doi: 10.1007/s12272-014-0527-x.
   Web of Science ®Google Scholar